CLSI M Quality Control for Commercial Microbial Identification Systems; Approved Guideline. Final document was approved through the CLSI voting process. – Publication of CLSI M Quality Control for. Commercial Microbial. Buy CLSI M50 A Ed. 1 () Quality Control For Commercial Microbial Identification Systems from SAI Global.
|Published (Last):||21 February 2009|
|PDF File Size:||15.47 Mb|
|ePub File Size:||8.66 Mb|
|Price:||Free* [*Free Regsitration Required]|
Proceed to Checkout Continue Shopping. You may delete a document from your Alert Profile at any time.
Clinical Laboratory Improvement Advisory Committee (CLIAC)
Again, as stated in the ASM letter to CMS, there are many tests in clinical microbiology where additional QC testing does nothing to prevent reporting erroneous results on patient’s isolates or samples. Results of the survey of the quality assurance for commercially prepared microbiology media. CMS stated that this action had nothing to do with the implementation of IQCP but was due to the fact that the CLSI documents must be purchased and are not freely available to the public.
CMS states that IQCP is a new, flexible QC option that provides the opportunity to tailor QC to your unique testing environment and patients and will establish the appropriate quality practices which will reduce the likelihood of errors occurring in your laboratory. NovemberVenue: In addition, the Committee provides advice and guidance on specific questions related to possible revision of the CLIA standards.
Your Alert Profile lists the documents that will be monitored.
Individualized Quality Control Plan (IQCP): Is It Value-Added for Clinical Microbiology?
The advice and guidance CLIAC provides clwi HHS pertains to general issues related to improvement in clinical laboratory quality and laboratory medicine practice. These data are critical to help clinical microbiologists understand the value in IQCP and to further motivate us to allocate resources to this time-consuming effort.
Errors in laboratory medicine can certainly have significant effects on patient care, and we in the clinical microbiology community clearly support quality improvement measures which have the potential to positively impact patient outcomes. Stakeholders expressed concerns at this meeting that manufacturers did not provide laboratories with sufficient information regarding QC and that a one-size-fits-all requirement for QC would not work with all new technologies.
CLSI MA – Quality Control for Commercial Microbial Identification Systems; Approved Guideline
Generally, CLIA ’67 affected large hospital and independent laboratories, while physician office laboratories and small laboratories were essentially clxi unregulated. We also understand that there are common errors in microbiology that need to be managed; however, it is difficult to see how the implementation of IQCP and the elimination of both EQC and the use of recommendations in CLSI standards and guidelines will have a positive effect for our patients.
Several decades ago, it was recognized that testing of QC strains by clsii user for commercially prepared media demonstrated few QC failures and imposed a substantial financial burden on microbiology laboratories.
The streamlined QC approach was developed following an evaluation of data provided by the American Society for Microbiology for a csli conducted to determine the QC failure rates of commercial MISs. The QC recommendations in the CLSI standards are supported by data demonstrating that following CLIA default QC daily testing of QC strains will not improve the quality of patient results for laboratories that clxi documented satisfactory performance with a specified amount of daily QC testing.
The clinical and anatomic pathology laboratory specialties represented include microbiology, immunology, chemistry, hematology, immunohematology, cytopathology, histopathology, genetic testing, and informatics. A discussion of the statistical considerations that support the CLSI recommendations for frequency of QC testing is available The power in these numbers is obvious, and there is ample evidence to categorize media as being exempt or nonexempt.
EQC primarily refers to those test systems that utilize internal controls. J Clin Microbiol Nearly laboratories provided data for nearly 10, lots of MIS.
It is anticipated that MA will be used extensively in the United States and internationally to reduce resources spent on excessive QC testing. Facebook Twitter Email Syndicate. The frequency of errors can be determined by reviewing historical data; however, m50a accurate determination of patient harm resulting lcsi these errors is highly variable and a nearly impossible task.
One other facet of the RA is to note both the frequency of occurrence and impact of possible laboratory errors. September 25, Content source: Author information Copyright and License information Disclaimer. It should be noted that these guidelines, along with the tenets of EQC, can still be used by clinical microbiology laboratories as a component of an IQCP. To this end, our clinical microbiology community is more than willing to have its members assist CMS in this endeavor.
It defines QC as the set of operations, processes, and procedures designed to monitor the measuring system to ensure the results are reliable for the intended clinical use. It would be more prudent for CMS to focus on measures that might be of greater benefit to patients and clinical microbiology than generating an IQCP. Likewise, the use of EQC for the past decade for our diagnostic microbiology test systems has proven reliable.
The data showed a failure rate of less than 0. There are three components to an IQCP: Notes The views expressed in this Commentary do not necessarily reflect the views of the journal or of ASM. The most recent survey, inevaluated overlots of over 32 million pieces of media. Links with this icon indicate that you are leaving the CDC website. Quality control for commercial microbial identification systems.
All five of the CLSI documents mentioned here are available and used by most clinical microbiology laboratories in the United States; they are data driven, evidence based, and have proven efficacy. For example, daily QC testing with antimicrobial susceptibility tests will m50–a prevent a laboratory from reporting results from a mixed population of organisms.
Last, a nonvoting liaison representing m50a laboratory industry participates on the Committee. Please first log in with a verified email before subscribing to alerts.